Trial Profile

Effectiveness and Safety of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease Treated With Immunomodulatory or Biological Drugs

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Feb 2023 Results of serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls, published in the Digestive and Liver Disease
11 Oct 2022 Results (n=809) assessing safety of Covid-19 Vaccine in Patients with Inflammatory Bowel Disease treated with immunomodulatory or bio-logical drugs, presented at the 30th United European Gastroenterology Week.
11 Oct 2022 Results assessing effectiveness and safety of COVID-19 vaccine in Patients with inflammatory Bowel Disease (IBD) Treated with Immuno-modulatory or Biological Drugs presented at the 30th United European Gastroenterology Week

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com